Cost-Minimization Analysis of Sacubitril/Valsartan and Ramipril in Hospitalized Heart Failure Patients at RSUP Dr. Kariadi Semarang
DOI:
https://doi.org/10.33759/jrki.v8i1.923Keywords:
Heart Failure; Cost-Minimization Analysis; Sacubitril-Valsartan; Ramipril; Healthcare Costs; Hospitalized PatientsAbstract
Heart failure represents a major public health challenge in Indonesia, characterized by high hospitalization rates and substantial healthcare costs. This study compared the economic efficiency of sacubitril-valsartan and ramipril in hospitalized heart failure patients through cost-minimization analysis. This study was conducted in a retrospective cross-sectional at RSUP Dr. Kariadi Semarang from January to December 2024, Analyzed 98 patients who received sacubitril-valsartan or ramipril in conjunction with beta-blockers and mineralocorticoid receptor antagonists, and did not undergo minor or major surgery during hospitalization, with data sourced from medical records, hospital systems, pharmacy, and finance departments. Patient baseline characteristics showed no significant differences in sex, occupation, or length of stay, though sacubitril-valsartan patients had more comorbidities and different insurance and education profiles. Length of stay averaged 5.78 days for ramipril and 6.18 days for sacubitril-valsartan, with no statistical difference. Total hospital costs reached 12,379,257 IDR per patient for ramipril versus 12,174,742 IDR for sacubitril-valsartan. Sacubitril-valsartan proves economically comparable to ramipril, offering a slight cost advantage from the payer perspective under equivalent clinical effectiveness. These findings support its integration into Indonesian heart failure protocols to optimize resource use amid budget constraints.
Downloads
References
Kemenkes RI. Profil Kesehatan Indonesia 2021. Kementerian Kesehatan RI; 2021.
Feng J, Zhang Y, Zhang J. Epidemiology and Burden of Heart Failure in Asia. JACC Asia. 2024;4(4):249-264. doi:10.1016/j.jacasi.2024.01.013
Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2
Kementerian Kesehatan Republik Indonesia. Laporan Nasional Riskesdas 2013. Badan Penelitian dan Pengembangan Kesehatan; 2013.
Kementerian Kesehatan Republik Indonesia. Laporan Nasional Riskesdas 2018. Badan Penelitian dan Pengembangan Kesehatan; 2019.
BPJS Kesehatan. Buku Statistik JKN 2016-2021. Dewan Jaminan Sosial Nasional; 2022.
PERKI. Pedoman Tatalaksana Gagal Jantung (3rd ed.). Published online 2023.
Kusumajaya H, Permatasari I. FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN CONGESTIVE HEART FAILURE (CHF) PASIEN. 2024;6(1).
Zakiyah N, Sinuraya RK, Kusuma AS, Suwantika AA, Lestari K. Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia. Clin Outcomes Res. 2021;Volume 13:863-872. doi:10.2147/CEOR.S322740
Marulin D, Zakiyah N, Puspitasari IM, Rahayu C. Analisis Efektivitas Biaya Penggunaan Sacubitril/Valsartan Dibandingkan Ramipril pada Pasien Gagal Jantung dengan Hipertensi di RSUP dr. Hasan Sadikin Bandung. Indones J Clin Pharm. 2025;12(2):86-97. doi:10.15416/ijcp.2023.12.2.86
Gordin J, Fonarow GC. New Medications for Heart Failure. Trends Cardiovasc Med. 2016;26(6):485-492. doi:10.1016/j.tcm.2016.02.008
Rezapour A, Azari S, Arabloo J, et al. Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review. J Tehran Univ Heart Cent. Published online January 3, 2023. doi:10.18502/jthc.v17i4.11603
Febrinasari RP, Putra SE, Hafizhan M, Probandari A. Cost-Effectiveness of Sacubitril–Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. J Pharm Pract. 2022;36(4):915-924. doi:10.1177/08971900221087106
Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. Jama Cardiol. 2020;5(11):1236. doi:10.1001/jamacardio.2020.2822
Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. Jama. 2019;322(11):1085. doi:10.1001/jama.2019.12821
Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan. JACC Heart Fail. 2020;8(10):800-810. doi:10.1016/j.jchf.2020.06.020
NICE. Chronic Heart Failure in Adults : Diagnosis and Management. National Institute for Health and Care Excellence (NICE); 2025.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18). doi:10.1161/CIR.0000000000001063
Pfeffer MA, Claggett B, Lewis EF, et al. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022;145(1):87-89. doi:10.1161/circulationaha.121.057429
Causland FRM, McGrath MM, Claggett B, et al. Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights From PARADISE‐MI. Eur J Heart Fail. Published online 2024. doi:10.1002/ejhf.3386
Wu Y, Tian S, Rong P, et al. Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China. Front Pharmacol. 2020;11. doi:10.3389/fphar.2020.01101
Proudfoot C, Gautam R, Cristino J, Agrawal R, Thakur L, Tolley K. Model Parameters Influencing the Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure: Evidence From a Systematic Literature Review. Eur J Health Econ. 2022;24(3):453-467. doi:10.1007/s10198-022-01485-3
Liu X qi, He L shan, Huang J qing, Xiong L juan, Xia C, Lao H yan. Cost-effectiveness analyses of sacubitril-valsartan for heart failure. Heart Fail Rev. 2021;26(5):1119-1130. doi:10.1007/s10741-020-09956-6
Perera K, Ademi Z, Liew D, Zomer E. Sacubitril-Valsartan Versus Enalapril for Acute Decompensated Heart Failure: A Cost-Effectiveness Analysis. Eur J Prev Cardiol. 2019;28(9):966-972. doi:10.1177/2047487319878953
Giorgi M, Boissonnet C, Luque PS, et al. Cost-Effectiveness in Unstable Economies: The Case of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction in Argentina. Health Econ Rev. 2023;13(1). doi:10.1186/s13561-023-00427-w
Lim AH, Rahim NA, Zhao J, Cheung SYA, Lin Y. Cost Effectiveness Analyses of Pharmacological Treatments in Heart Failure. Front Pharmacol. 2022;13. doi:10.3389/fphar.2022.919974
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
Bhatt AS, Vaduganathan M, Claggett B, et al. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management. Jama Cardiol. 2023;8(11):1041. doi:10.1001/jamacardio.2023.3216
Kuan WC, Ademi Z, Lee SW, et al. Cost-Effectiveness Analysis of Angiotensin Receptor Neprilysin Inhibitor Compared With Angiotensin-Converting Enzyme Inhibitor Among Patients With Heart Failure With Reduced Ejection Fraction in Malaysia. Value Health Reg Issues. 2025;48:101118. doi:10.1016/j.vhri.2025.101118
Kuan WC, Sim R, Wong WJ, et al. Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review. Value Health. 2023;26(10):1558-1576. doi:10.1016/j.jval.2023.05.011
Correale M, Mallardi A, Mazzeo P, et al. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. IJC Heart Vasc. 2020;27:100486. doi:10.1016/j.ijcha.2020.100486
Fu M, Pivodic A, Käck O, Costa-Scharplatz M, Dahlström U, Lund LH. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction. Clin Res Cardiol. 2023;112(1):167-174. doi:10.1007/s00392-022-02124-w
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jurnal Riset Kefarmasian Indonesia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
